metformin has been researched along with Mental Disorders in 17 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 24-week pilot study assessed the efficacy, tolerability, and safety of adjunctive metformin versus placebo for the prevention of olanzapine-associated weight gain in community-dwelling adult patients with schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features." | 9.22 | A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population. ( Rado, J; von Ammon Cavanaugh, S, 2016) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 9.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "The objective of this study was to perform the first systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effects of metformin on weight gain in children and adolescents treated with SGAs." | 8.98 | Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis. ( Cortese, S; Delorme, R; Ellul, P, 2018) |
| "There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities." | 8.88 | Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. ( Curtis, J; Myles, N; Newall, H; Samaras, K; Shiers, D; Ward, PB, 2012) |
| " However, the antihyperglycaemic agent metformin appears promising in some recent studies and we review the literature that evaluates metformin for limiting or reversing atypical antipsychotic drug-induced weight gain and glucose metabolism dysregulation." | 8.86 | Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. ( Fredrickson, SK; Hasnain, M; Vieweg, WV, 2010) |
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 7.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| "There is considerable evidence that metformin reduces weight gain associated with antipsychotic medication." | 7.85 | Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. ( Galletly, C; Myles, H; Smith, C, 2017) |
| "This 24-week pilot study assessed the efficacy, tolerability, and safety of adjunctive metformin versus placebo for the prevention of olanzapine-associated weight gain in community-dwelling adult patients with schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features." | 5.22 | A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population. ( Rado, J; von Ammon Cavanaugh, S, 2016) |
| "Metformin was assessed as an interventional medication for weight gain in children and adolescents taking atypical antipsychotic agents." | 5.14 | Metformin for weight control in pediatric patients on atypical antipsychotic medication. ( Breeze, JL; Bregman, H; Frazier, JA; Noyes, N; Shin, L, 2009) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 5.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "The objective of this study was to perform the first systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effects of metformin on weight gain in children and adolescents treated with SGAs." | 4.98 | Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis. ( Cortese, S; Delorme, R; Ellul, P, 2018) |
| "There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities." | 4.88 | Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. ( Curtis, J; Myles, N; Newall, H; Samaras, K; Shiers, D; Ward, PB, 2012) |
| " However, the antihyperglycaemic agent metformin appears promising in some recent studies and we review the literature that evaluates metformin for limiting or reversing atypical antipsychotic drug-induced weight gain and glucose metabolism dysregulation." | 4.86 | Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. ( Fredrickson, SK; Hasnain, M; Vieweg, WV, 2010) |
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 3.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| "There is considerable evidence that metformin reduces weight gain associated with antipsychotic medication." | 3.85 | Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. ( Galletly, C; Myles, H; Smith, C, 2017) |
| "The prevalence of type 2 diabetes is increased in individuals with mental disorders." | 2.72 | Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries. ( Ajjan, RA; Al Azdi, Z; Aslam, F; Churchill, R; Mishu, MP; Philip, S; Siddiqi, N; Stubbs, B; Tirbhowan, N; Uphoff, E; Wright, J, 2021) |
| "People with severe mental illness (SMI) have reduced life expectancy compared with the general population, which can be explained partly by their increased risk of diabetes." | 2.55 | The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. ( Ajjan, RA; Alderson, SL; Gilbody, S; Hewitt, C; Holt, RI; Hosali, P; Hughes, T; Kayalackakom, T; Kellar, I; Lewis, H; Mahmoodi, N; McDermid, K; Siddiqi, N; Smith, RD; Stubbs, B; Taylor, J; Wright, JM, 2017) |
| "Metformin has the potential effect of inducing hippocampal neurogenesis, and additional studies of this drug are warranted in patients with mood or cognitive disorders." | 2.49 | A "glucose eater" drug as a therapeutic agent in psychiatry. ( Howland, RH, 2013) |
| "Children with psychiatric illness are at greater risk for obesity than those in the general population." | 2.44 | An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. ( Bregman, H; Frazier, J; Noyes, N; Shin, L, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, SM | 1 |
| Stogios, N | 1 |
| Mc Namara, KP | 1 |
| Alzubaidi, H | 1 |
| Murray, M | 1 |
| Samorinha, C | 1 |
| Dunbar, JA | 1 |
| Versace, VL | 1 |
| Castle, D | 1 |
| Bakkedal, C | 1 |
| Persson, F | 1 |
| Kriegbaum, M | 1 |
| Andersen, JS | 1 |
| Grant, MK | 1 |
| Mohr, GH | 1 |
| Lind, BS | 1 |
| Andersen, CL | 1 |
| Christensen, MB | 1 |
| Siersma, V | 1 |
| Rozing, MP | 1 |
| Mishu, MP | 1 |
| Uphoff, E | 1 |
| Aslam, F | 1 |
| Philip, S | 1 |
| Wright, J | 1 |
| Tirbhowan, N | 1 |
| Ajjan, RA | 2 |
| Al Azdi, Z | 1 |
| Stubbs, B | 2 |
| Churchill, R | 1 |
| Siddiqi, N | 2 |
| Dy, ABC | 1 |
| Tassone, F | 1 |
| Eldeeb, M | 1 |
| Salcedo-Arellano, MJ | 1 |
| Tartaglia, N | 1 |
| Hagerman, R | 1 |
| Hendrick, V | 1 |
| Dasher, R | 1 |
| Gitlin, M | 1 |
| Parsi, M | 1 |
| Smith, C | 1 |
| Myles, H | 1 |
| Galletly, C | 1 |
| Ellul, P | 1 |
| Delorme, R | 1 |
| Cortese, S | 1 |
| Howland, RH | 1 |
| Rado, J | 1 |
| von Ammon Cavanaugh, S | 1 |
| Taylor, J | 1 |
| Hewitt, C | 1 |
| Alderson, SL | 1 |
| Gilbody, S | 1 |
| Holt, RI | 1 |
| Hosali, P | 1 |
| Hughes, T | 1 |
| Kayalackakom, T | 1 |
| Kellar, I | 1 |
| Lewis, H | 1 |
| Mahmoodi, N | 1 |
| McDermid, K | 1 |
| Smith, RD | 1 |
| Wright, JM | 1 |
| Shin, L | 2 |
| Bregman, H | 2 |
| Breeze, JL | 1 |
| Noyes, N | 2 |
| Frazier, JA | 1 |
| Hasnain, M | 1 |
| Vieweg, WV | 1 |
| Fredrickson, SK | 1 |
| Ohaeri, JU | 1 |
| Akanji, AO | 1 |
| Newall, H | 1 |
| Myles, N | 1 |
| Ward, PB | 1 |
| Samaras, K | 1 |
| Shiers, D | 1 |
| Curtis, J | 1 |
| Klein, DJ | 1 |
| Cottingham, EM | 1 |
| Sorter, M | 1 |
| Barton, BA | 1 |
| Morrison, JA | 1 |
| Frazier, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)[NCT03862950] | Phase 2 | 120 participants (Anticipated) | Interventional | 2019-05-24 | Recruiting | ||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for metformin and Mental Disorders
| Article | Year |
|---|---|
Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?
Topics: Antipsychotic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Re | 2022 |
Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antioxidants; Antipsychotic Agents; Blood Glucose; Bo | 2021 |
Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin.
Topics: Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; | 2017 |
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Antipsychotic Agents; Child; Humans; Hypoglycemic Agents; Mental Disorders; Metformin; W | 2018 |
A "glucose eater" drug as a therapeutic agent in psychiatry.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Depressive Disorder, Major; Diabetes Mellitus, Typ | 2013 |
The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Fasting; Glycated Hemoglobin; Humans; Mental Disorders; Met | 2017 |
Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Glucose Metabolism Disorders; Guidelines as Topic; Hu | 2010 |
Metabolic syndrome in severe mental disorders.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Environment; Humans; Lif | 2011 |
Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agen | 2012 |
An overview of obesity in children with psychiatric disorders taking atypical antipsychotics.
Topics: Adolescent; Antipsychotic Agents; Appetite Depressants; Child; Child, Preschool; Cognitive Behaviora | 2008 |
3 trials available for metformin and Mental Disorders
| Article | Year |
|---|---|
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Double-Blind Method; Drug | 2016 |
Metformin for weight control in pediatric patients on atypical antipsychotic medication.
Topics: Adolescent; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Female; Humans; Hypoglycemi | 2009 |
A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Diabetes Melli | 2006 |
4 other studies available for metformin and Mental Disorders
| Article | Year |
|---|---|
Cardiovascular Health in Severe Mental Illness: Potential Role for Metformin.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mental Disorders; M | 2022 |
Diabetes treatment for persons with severe mental illness: A registry-based cohort study to explore medication treatment differences for persons with type 2 diabetes with and without severe mental illness.
Topics: Adult; Cardiovascular Agents; Cohort Studies; Diabetes Mellitus, Type 2; Glucose; Humans; Mental Dis | 2023 |
Metformin as targeted treatment in fragile X syndrome.
Topics: Adult; Animals; Child; Child, Preschool; Diabetes Mellitus, Type 2; Female; Fragile X Syndrome; Gluc | 2018 |
Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Humans; Mental Disorders; Metformin; Obesity; Risk Fa | 2017 |